• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 4
  3. Author

Online ISSN: 2515-8260

Volume9, Issue4

A Study of Serum Testosterone Levels in Prostate Cancer

    Dr. Sabbani Krishna Murthy

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 4, Pages 3511-3519

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Prostate cancer (PCa) diagnoses have been linked to low testosterone levels. Hormonal levels in PCa-affected men, particularly those who underwent radical prostatectomy, have been linked to poor prognostic variables. The current study aimed to establish a link between hormone levels and PCa prognostic elements in PCa-affected men before starting treatment.
Methods: The study sample was obtained from the patients referred to the Department of Urology based on the inclusion and exclusion criteria. All prostate cancer participants in this study were evaluated at the time of admission using a thorough clinical examination, baseline blood tests, serum PSA, serum testosterone, and Gleason grading (TRUS biopsy), which includes the primary, secondary, and total Gleason scores or sum Imaging studies (bone scan, CECT/MRI abdomen and pelvis, and chest x-ray). Radical prostatectomy (RP) was recommended for patients with localized prostate cancer, including those with clinical stage T1 and T2 disease without regional pelvic nodal involvement and metastasis.
Results: The patients in the low testosterone group I had a higher overall tumor stage on clinical evaluation compared to the normal testosterone group. The p-value is found statistically significant. The overall pathological T staging is not statistically significant the patients in low testosterone (group I) had higher T3 disease than group II patients. The p-value is not statistically significant. The Postoperative pathological nodal status between the two groups was compared. The Patients in the low testosterone group I had more proportion of pathological lymph nodal involvement than patients in the normal testosterone group. P value was found to be statistically significant (p = 0.0121).
Conclusion: The higher percentage of predominant Gleason pattern 4, a sign of aggressive prostate cancer, is linked to low total serum testosterone. When compared to patients with normal blood testosterone levels, patients with low serum testosterone levels had higher serum PSA values. Patients who underwent radical prostatectomy and had low testosterone levels had a higher percentage of positive surgical margins, extracapsular extension, and seminal venous invasion, all of which are possible signs of aggressive prostate cancer behavior.
Keywords:
  • PDF (272 K)
  • XML
(2022). A Study of Serum Testosterone Levels in Prostate Cancer. European Journal of Molecular & Clinical Medicine, 9(4), 3511-3519.
Dr. Sabbani Krishna Murthy. "A Study of Serum Testosterone Levels in Prostate Cancer". European Journal of Molecular & Clinical Medicine, 9, 4, 2022, 3511-3519.
(2022). 'A Study of Serum Testosterone Levels in Prostate Cancer', European Journal of Molecular & Clinical Medicine, 9(4), pp. 3511-3519.
A Study of Serum Testosterone Levels in Prostate Cancer. European Journal of Molecular & Clinical Medicine, 2022; 9(4): 3511-3519.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 37
  • PDF Download: 46
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus